The Lancet has announced a new Commission on colorectal cancer, responding to projections that the disease will claim 1.6 million lives per year by 2040. Currently, colorectal cancer accounts for about 10% of all cancer incidence and nearly 1 million deaths worldwide between 2020 and 2022. Its epidemiological landscape is shifting rapidly toward younger patients, more advanced stages at diagnosis, and a higher proportion of left-sided tumors.
The initiative comes as global health leaders warn that current trends are unsustainable. Without coordinated action, the burden will increase substantially in the coming decades. The Commission aims to focus on early detection, prevention strategies, and equitable access to care — areas where gaps remain stark across low- and middle-income countries.
Projections show more than 3.2 million new cases and 1.6 million deaths annually by 2040. The data underscore the urgency of rethinking screening guidelines, which in many countries still begin at age 50 despite rising incidence among younger adults. The Commission will also examine disparities in treatment outcomes between wealthy and poorer nations.
If these trends hold, health systems worldwide will face mounting pressure on surgical, oncological, and palliative care resources. Public health campaigns may need to target younger populations, and policymakers will be forced to reevaluate screening ages and funding priorities. The Commission's recommendations could reshape national cancer strategies.
Critics caution that Commissions often produce ambitious but unimplemented recommendations. Previous Lancet Commissions on other cancers have faced delays in translating findings into policy action, especially in resource-limited settings.